Hoping for a checkmate, generic drugmakers petitioned the Supreme Court Monday to either clear the board for a late May launch of generic versions of Copaxone or force Teva Pharmaceuticals USA Inc. to post a hefty bond to reimburse them for their losses if its final patent on the multiple sclerosis (MS) drug remains struck down on appeal.